Business Context and Reporting Period
This Form 8-K is a current report filed by Derycz Scientific, Inc. (not Research Solutions, Inc.) on November 5, 2010. The filing details significant changes to the Company's Board of Directors and associated compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and equity compensation events.
Material Changes
- Board Expansion: The Board of Directors increased the number of directors from three (3) to five (5).
- Director Resignation: Mr. Scott Ahlberg resigned as a director. The filing states he did not resign due to any disagreement with the Corporation regarding operations, policies, or practices.
- New Appointments:
- General Merrill McPeak: Appointed to fill the vacancy created by Mr. Ahlberg. He is a retired U.S. Air Force Chief of Staff with extensive board experience (e.g., TWA, Tektronix, Del Global Technologies).
- Mr. Scott Ogilvie: Appointed to a new seat. He is the Founder and President of AFIN International, Inc., with expertise in Middle East and North Africa (MENA) markets.
- Mr. Gregory Suess: Appointed to a new seat. He is a founding partner of ROAR and an attorney specializing in media and entertainment law.
Compensatory Arrangements and Risks
- Stock Warrants: On November 5, 2010, the Corporation issued Common Stock Purchase Warrants to each of the three new directors (McPeak, Ogilvie, and Suess).
- Terms: Each warrant allows the purchase of up to 50,000 shares at an exercise price of $1.25 per share.
- Vesting Schedule: 12,500 shares vest on December 31, 2010, March 31, 2011, June 30, 2011, and September 30, 2011.
- Expiration: November 5, 2015.
- Indemnification: The Corporation entered into Indemnification Agreements with each new director, protecting them against expenses and judgments incurred in good faith while serving the Corporation.
Investor Verification Checklist
- Verify the total number of outstanding shares and the potential dilution impact of the 150,000 new warrants issued.
- Confirm the current market price of the stock relative to the $1.25 warrant exercise price.
- Review the full text of the Indemnification Agreement (Exhibit 10.1) for specific limitations on liability.
- Check subsequent filings to confirm the vesting of warrants and the continued tenure of the new directors.